Literature DB >> 24650695

Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT.

Lei Yin1, Hui Li2, Ai-Jun Li1, Wan Yee Lau3, Ze-Ya Pan1, Eric C H Lai3, Meng-Chao Wu1, Wei-Ping Zhou4.   

Abstract

BACKGROUND & AIMS: The aim of this randomized comparative trial (RCT) is to compare partial hepatectomy (PH) with transcatheter arterial chemoembolization (TACE) to treat patients with resectable multiple hepatocellular carcinoma (RMHCC) outside of Milan Criteria.
METHODS: This RCT was conducted on 173 patients with RMHCC outside of Milan Criteria (a solitary tumor up to 5 cm or multiple tumors up to 3 in number and up to 3 cm for each tumor) who were treated in our centre from November 2008 to September 2010. The patients were randomly assigned to the PH group or the TACE group. The primary outcome measure was overall survival (OS) from the date of treatment. A multivariate Cox proportional hazards regression analysis was performed to assess the prognostic risk factors associated with OS.
RESULTS: The 1-, 2-, and 3-year OS rates were 76.1%, 63.5%, and 51.5%, respectively, for the PH group compared with 51.8%, 34.8%, and 18.1%, respectively, for the TACE group (Log-rank test, χ(2)=24.246, p<0.001). Multivariate Cox proportional hazards regression analysis revealed the type of treatment (hazard ratio, 0.434; 95% CI, 0.293 to 0.644, p<0.001), number of tumor (hazard ratio, 1.758; 95% CI, 1.213 to 2.548, p=0.003) and gender (hazard ratio, 0.451; 95% CI, 0.236 to 0.862, p=0.016) were significant independent risk factors associated with OS.
CONCLUSIONS: PH provided better OS for patients with RMHCC outside of Milan Criteria than conventional TACE. The number of tumor and gender were also independent risk factors associated with OS for RMHCC.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Multiple hepatocellular carcinoma; Overall survival; Partial hepatectomy; RCT; Transcatheter arterial chemoembolization

Mesh:

Year:  2014        PMID: 24650695     DOI: 10.1016/j.jhep.2014.03.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  100 in total

1.  Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma: a Letter to Response.

Authors:  Wei Liu; Jian-Guo Zhou; Bao-Cai Xing
Journal:  J Gastrointest Surg       Date:  2015-10-05       Impact factor: 3.452

2.  Intermediate-stage HCC--upfront resection can be feasible.

Authors:  Jian-Hong Zhong; Shi-Dong Lu; Yan-Yan Wang; Liang Ma; Le-Qun Li
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 3.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

4.  Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients?

Authors:  Federica Cipriani; Corrado Fantini; Francesca Ratti; Roberto Lauro; Hadrien Tranchart; Mark Halls; Vincenzo Scuderi; Leonid Barkhatov; Bjorn Edwin; Roberto I Troisi; Ibrahim Dagher; Paolo Reggiani; Giulio Belli; Luca Aldrighetti; Mohammad Abu Hilal
Journal:  Surg Endosc       Date:  2017-07-17       Impact factor: 4.584

5.  Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

6.  Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Authors:  Qiang Gao; Xiao-Ying Wang; Jian Zhou; Jia Fan
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

7.  Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.

Authors:  Rusi Zhang; Lujun Shen; Long Zhao; Zhaoming Guan; Qifeng Chen; Wang Li
Journal:  Diagn Interv Radiol       Date:  2018-07       Impact factor: 2.630

8.  Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes.

Authors:  Yun Xu; Qiang Shen; Pei Liu; Zhongqi Xu; Panpan Wu; Zhenghua Lu; Yi Chen; Bin Huang; Guojun Qian
Journal:  Eur Radiol       Date:  2017-02-10       Impact factor: 5.315

9.  Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Authors:  Biao Yang; Bo Zheng; MaoNan Yang; Zhu Zeng; FangYun Yang; Ji Pu; ChunLin Li; ZhengYin Liao
Journal:  Hepatol Int       Date:  2018-08-02       Impact factor: 6.047

Review 10.  Liver resection for intermediate hepatocellular carcinoma.

Authors:  Peng-Sheng Yi; Ming Zhang; Ji-Tong Zhao; Ming-Qing Xu
Journal:  World J Hepatol       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.